NSE: DIVISLAB · 11 November 2026
- Divi S Laboratories has risen 10.04% over 2 trading sessions; today's move is -1.81%.
- Divi's Laboratories submitted its un-audited financial results for the quarter and half year ended September 30, 2026, to the stock exchanges. The company also hosted its scheduled earnings call for institutional investors and analysts on the same day to discuss operating performance.
- Trading volume was 0.75 times the 20-day average daily volume.
Divi S Laboratories share price: 10.04% rise over 2 trading sessions
Divi's Laboratories Ltd (DIVISLAB) shares declined 1.81% during the trading session, moving within a day's range of ₹11,268.50 and ₹11,683.50 after opening at ₹11,683.50.
The broader market exhibited positive momentum, with the benchmark Nifty gaining 1.23%, whereas the sector-specific Nifty Pharma index moved lower by 0.52%. Divi's Laboratories' decline thus aligned closer with sectoral weakness than the broader market's gains, following a strong short-term run that included a 5-day return of 12.84% and a 20-day return of 20.48%.
Company disclosures indicate that the quarterly financial results for the period ended September 30, 2026, were submitted to the exchange on 07-Nov-2026, alongside earnings call proceedings. While these ongoing operational reports provide fundamental context regarding the active pharmaceutical ingredient manufacturer's business performance and its recent capacity expansion initiatives at Unit 3 near Kakinada, no single confirmed same-day catalyst was explicitly linked to today's downward price movement, suggesting typical profit-taking following recent sharp gains.
5.94 lakh shares traded by 11 November 2026 · 10:30 AM IST. This compares with a 20-day average daily volume of 7.95 lakh shares (0.75 times). The five-day average daily volume was 10.91 lakh shares. Separately, the NSE report for 9 November 2026 showed 7.88 lakh shares delivered, representing 30.49% of that day’s traded volume. The same report recorded 281,051 trades.
The stock's decline of 1.81% coincides with sector-wide weakness in the Nifty Pharma index and follows a sharp preceding rally (12.06% return over the prior trading session and 12.84% over 5 days). No specific negative corporate announcement was made today, pointing towards routine consolidation and profit-booking.
Latest Company Developments
Divi's Laboratories submitted its un-audited financial results for the quarter and half year ended September 30, 2026, to the stock exchanges. The company also hosted its scheduled earnings call for institutional investors and analysts on the same day to discuss operating performance.
Quarterly financial updates provide the primary quantitative baseline for assessing revenue growth, operating margins, and the ongoing execution of capacity expansion plans.
The company successfully convened its 36th Annual General Meeting through video conferencing, where shareholders approved the audited financial statements for the financial year ended March 31, 2026. A final dividend of ₹30 per equity share was also adopted, with a record date established on July 24, 2026.
Confirms formal shareholder approval of annual accounts and dividend payouts, reflecting consistent capital return to equity holders.
The company announced the retirement of Mr. L. Ramesh Babu, Vice President (Procurement), and Mr. D. Madhu Babu, Vice President (Projects), effective from the close of business hours on July 31, 2026. The transition was formally notified to regulatory exchanges in compliance with listing regulations.
Involves key management transitions in critical operational domains such as procurement and infrastructure execution.
Divi's Laboratories Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
Divi's Laboratories Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
Ownership & Transaction Activity
Mutual Fund Holdings
Mutual funds held 14.66% on 30 September 2026. This compares with 13.87% on 30 June 2026, a change of +0.79 percentage points.
The filing reported 49 MF/UTI holders.
What to Watch Next
- Execution progress and commercial ramp-up at the Greenfield Unit 3 facility near Kakinada
- Sustained delivery participation relative to the 30.49% delivery rate recorded on 09-Nov-2026
- Performance trends in complex APIs, custom synthesis, and peptide manufacturing segments
- Sectoral trajectory of the Nifty Pharma index and broader healthcare outsourcing demand
Other Dated Coverage
- Divi S Laboratories Share Price Jumps 14.54% Intraday, Closes 4.22% Higher | 9 November 2026 — 9 November 2026
- Divi S Laboratories Share Price Today: Why DIVISLAB Is Falling 3.12% | 23 October 2026 — 23 October 2026
- Divi S Laboratories Share Price Today: Why DIVISLAB Is Rising 0.40% | 7 October 2026 — 7 October 2026
More Divi S Laboratories news and dated analysis →
Frequently Asked Questions
What is the latest Divi S Laboratories company news?
Divi's Laboratories submitted its un-audited financial results for the quarter and half year ended September 30, 2026, to the stock exchanges. The company also hosted its scheduled earnings call for institutional investors and analysts on the same day to discuss operating performance.
How strong was Divi S Laboratories’s trading volume?
5.94 lakh shares traded, 0.75 times the 20-day average daily volume. The price and volume data are dated 11 November 2026 · 10:30 AM IST.
Do the mutual-fund figures show buying today?
They show holdings on 30 September 2026. Quarterly holdings do not identify purchases made on the article date.
Research & analysis: WittyTrades Research Desk
Reviewed by: Mohanish Sanghavi — SEBI Registered Research Analyst
Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.